Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance.
about
9th Hatter Biannual Meeting: position document on ischaemia/reperfusion injury, conditioning and the ten commandments of cardioprotectionTicagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An UpdateWhen is the Best Time for the Second Antiplatelet Agent in Non-St Elevation Acute Coronary Syndrome?P2Y12 receptors: structure and functionSwitching between ticagrelor and clopidogrel in patients who underwent percutaneous coronary intervention: insight into contemporary practice in Chinese patientsThe clinical efficacy and safety evaluation of ticagrelor for acute coronary syndrome in general ACS patients and diabetic patients: A systematic review and meta-analysis.Ticagrelor-Associated Conduction Disorder: A Case Report and Review of the Literature.The platelet: life on the razor's edge between hemorrhage and thrombosis.Ticagrelor Does Not Inhibit Adenosine Transport at Relevant Concentrations: A Randomized Cross-Over Study in Healthy Subjects In Vivo.Ticagrelor versus clopidogrel in real-world patients with ST elevation myocardial infarction: 1-year results by propensity score analysisReducing Microvascular Dysfunction in Revascularized Patients with ST-Elevation Myocardial Infarction by Off-Target Properties of Ticagrelor versus Prasugrel. Rationale and Design of the REDUCE-MVI Study.Low-dose ticagrelor yields an antiplatelet efficacy similar to that of standard-dose ticagrelor in healthy subjects: an open-label randomized controlled trial.Inverse agonism at the P2Y12 receptor and ENT1 transporter blockade contribute to platelet inhibition by ticagrelor.Novel antiplatelet agents in acute coronary syndrome.Ticagrelor: a review of its use in adults with acute coronary syndromes.Randomized Trial Comparing the Effects of Ticagrelor Versus Clopidogrel on Myocardial Perfusion in Patients With Coronary Artery Disease.A head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized study.Role of Genetic Testing in Patients undergoing Percutaneous Coronary Intervention.Antiplatelet drugs: which targets for which treatments?Antiplatelet therapy in acute coronary syndromes.A Safety Evaluation of Cangrelor in Patients Undergoing PCI.Ticagrelor mitigates ischaemia-reperfusion induced vascular endothelial dysfunction in healthy young males - a randomized, single-blinded study.Effects of P2Y12 receptor antagonists beyond platelet inhibition--comparison of ticagrelor with thienopyridinesTicagrelor for the treatment of atherosclerotic disease: insights from the PARTHENON clinical development program.Pharmacokinetics and pharmacodynamics of ticagrelor in the treatment of cardiac ischemia.Adenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases.Ticagrelor Compared with Clopidogrel Increased Adenosine and Cyclic Adenosine Monophosphate Plasma Concentration in Acute Coronary Syndrome Patients.Long-Term Use of Ticagrelor in Patients with Coronary Artery Disease.Antithrombotic therapy for patients with STEMI undergoing primary PCI.Remote Ischemic Conditioning for Patients With STEMI.Effects of autologous platelet transfusion on platelet inhibition in ticagrelor-treated and clopidogrel-treated subjects.Ticagrelor regulates osteoblast and osteoclast function and promotes bone formation in vivo via an adenosine-dependent mechanism.Pharmacokinetics and pharmacodynamics of ticagrelor when treating non-ST elevation acute coronary syndromes.Structural and functional characterization of a specific antidote for ticagrelor.Intracellular adenosine regulates epigenetic programming in endothelial cells to promote angiogenesis.Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trials.PRotective Effect on the coronary microcirculation of patients with DIabetes by Clopidogrel or Ticagrelor (PREDICT): study rationale and design. A randomized multicenter clinical trial using intracoronary multimodal physiology.The reversible P2Y12 antagonist ACT-246475 causes significantly less blood loss than ticagrelor at equivalent antithrombotic efficacy in rat.The Role of Platelet-Derived ADP and ATP in Promoting Pancreatic Cancer Cell Survival and Gemcitabine Resistance.Effects of four antiplatelet/statin combined strategies on immune and inflammatory responses in patients with acute myocardial infarction undergoing pharmacoinvasive strategy: Design and rationale of the B and T Types of Lymphocytes Evaluation in Ac
P2860
Q26750797-F9FC3E61-C269-40C1-845E-35F53415F1ACQ27006031-AF29E7CC-CDC3-42DD-ABCD-A75B995D8540Q28072343-836D258D-2C55-418A-9363-DC67EAB14F5AQ28264649-E9323E11-57D5-4880-A8DF-46E9E2665947Q33646807-F64B99BC-72F2-4F90-87A6-850043638577Q33699370-2F9B679E-6C48-46D1-8B57-55DBB2AB3C27Q33893920-992EBA2B-97DA-408C-96B5-00B760F1373EQ34175105-C1F0FB49-12EC-4BB7-B1B8-B0544AF05EFBQ35824259-8C9C8E9D-2A75-45BE-9AED-29E87BA048A7Q36337254-475D878E-ED8F-4BBB-A387-F809CF01F7ECQ36918428-25A15A9E-3CA6-4AF7-BE5E-ECF231258BC5Q37198888-05EF7054-5C4E-43B5-82DA-79C953D69AB9Q37509443-9971D135-9980-4BE4-9AC7-A24D64AFB5C7Q38257119-AAD7622E-598B-40BA-9EB5-6721177662DEQ38352069-9C80CC9E-1FED-4342-8987-7F442B9313BAQ38377285-03ED2EB5-9038-4C39-B96B-ED186416CE53Q38396256-124A7DEC-D253-45B3-AA47-E165810580F3Q38401281-7F585A63-8ED1-4CEC-B602-A1CA950E8D57Q38543308-F75A6CC9-B1E0-469B-B02D-01113168E25CQ38570608-8C581898-E510-4213-8849-3750082119A6Q38672923-EDD422FF-9D53-4948-8938-49CA4014E11CQ38675528-713342D1-F4DE-4420-94F1-D664427DFCC2Q38694069-C2E85DD0-762D-4064-AAEF-A1EC98D1EEB9Q38869502-D6189A54-CEC8-4CE4-800A-2491A164073FQ38974884-0A43FF50-5337-418A-BF73-B55F6B9763DAQ39004042-82350A63-70C4-4641-80F3-E0872DE16A5EQ39040803-D3A63C34-5ABD-4A36-A9CC-88DC10760319Q39093174-64BEFCC2-F798-4A41-8056-AA03F8A19A53Q39147735-4336A34C-E61B-44FD-A577-951844B39BEFQ39222527-40C96536-958F-4541-88B3-94DE818B107FQ39366233-FD3A52E8-F5D8-4E1C-8C20-9D382D3DD367Q40471318-7E3D5992-AD29-46A8-A915-DB9587CDE1BEQ41060485-DD6531A4-A6E3-462E-9383-938F8A5D63CFQ41194895-72DA5EB9-101F-4086-9469-307F5A7D795AQ41601038-DD7D4DAC-ACB2-4CE6-90AA-C5DCE2DA676BQ41708497-C82067A0-2656-45FB-AC96-90AB26C8A900Q42254531-35BC1A01-6A40-4E0F-86C5-07413D3ED0F6Q42285709-DAA8D041-F5EF-408C-A814-0EFB4AA79AD7Q42991719-B0B82E99-068F-4047-945D-BD7925C9E4D9Q47095431-02714A04-34AF-41BF-8480-4EB8DCF824DD
P2860
Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance.
@en
type
label
Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance.
@en
prefLabel
Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance.
@en
P1476
Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance.
@en
P2093
Sven Nylander
P304
P356
10.1016/J.JACC.2014.03.031
P407
P577
2014-04-23T00:00:00Z